A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Thomas Jefferson University
Columbia University
Theseus Pharmaceuticals
Kyowa Kirin Co., Ltd.
Institut Cancerologie de l'Ouest
Repos Pharma
Generic Devices Consulting, Inc.